
SW063058
CAS No. 533876-30-1
SW063058( SW-063058 )
Catalog No. M14896 CAS No. 533876-30-1
SW063058 is a small molecule that selectively disrupt Beclin 1/Bcl-2 binding as compared to Bax/Bcl-2 and Bim/Bcl-2 binding and induces autophagic flux at concentrations with minimal cytotoxicity.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameSW063058
-
NoteResearch use only, not for human use.
-
Brief DescriptionSW063058 is a small molecule that selectively disrupt Beclin 1/Bcl-2 binding as compared to Bax/Bcl-2 and Bim/Bcl-2 binding and induces autophagic flux at concentrations with minimal cytotoxicity.
-
DescriptionSW063058 is a small molecule that selectively disrupt Beclin 1/Bcl-2 binding as compared to Bax/Bcl-2 and Bim/Bcl-2 binding and induces autophagic flux at concentrations with minimal cytotoxicity.
-
In Vitro——
-
In Vivo——
-
SynonymsSW-063058
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorBcl-2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number533876-30-1
-
Formula Weight565.181
-
Molecular FormulaC22H15BrFIN2O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC1C(=O)NC2=C(C=C(C=C2)Br)C(N1C(=O)C3=CC=CC=C3I)C4=CC=C(C=C4)F
-
Chemical Name7-bromo-5-(4-fluorophenyl)-4-(2-iodobenzoyl)-1,3,4,5-tetrahydro-2H-benzo[e][1,4]diazepin-2-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chiang WC, et al. ACS Chem Biol. 2018 Jun 21. doi: 10.1021/acschembio.8b00421.
molnova catalog



related products
-
BCL6 inhibitor 14
BCL6 inhibitor 14 is a potent BCL-6 inhibitor with FRET IC50 of 63 nM.
-
Sonrotoclax
Sonrotoclax is a potent, orally active inhibitor of Bcl2, demonstrating effective cell-killing activity against a range of lymphoma and leukemia cell lines .
-
BCL6-IN-6
BCL6-IN-6 is an inhibitor of Bcl-6 and can be used in studies about diffuse large B-cell lymphoma. BCL6-IN-6 blocks the interaction of Bcl-6 with its corepressors and dose-dependently reactivates Bcl-6 target genes.